Table 3.
Distribution of chronic comorbidity and infections in cases and controls by country in study of association between pandemic influenza A (H1N1) 2009 vaccine and Guillain-Barré syndrome. Figures are numbers (percentages)
| Netherlands | Sweden | UK | France | Denmark | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Control (n=227) | Case (n=25) | Control (n=60) | Case (n=18) | Control (n=300) | Case (n=30) | Control (n=21) | Case (n=7) | Control (n=590)* | Case (n=24) | ||||||
| Chronic comorbidity | |||||||||||||||
| Autoimmune disease | 6 (3) | 2 (8) | 4 (7) | 0 | 47 (16) | 8 (27) | 0 | 0 | NA | 0 | |||||
| History of Guillain-Barré | 0 | 1 (4) | 0 | 0 | 0 | 1 (3) | 0 | 0 | NA | 1 (4) | |||||
| Epstein Barr virus | 12 (5) | 2 (8) | 0 | 0 | 1 (0.3) | 1 (3) | 0 | 0 | NA | 0 | |||||
| Malignancy | 12 (5) | 1 (4) | 4 (7) | 2 (11) | 16 (5) | 2 (7) | 3 (14) | 1 (14) | NA | 1 (4) | |||||
| Immune compromised | 5 (2) | 1 (4) | 0 | 1 (6) | 26 (9) | 4 (13) | 2 (10) | 0 | NA | 0 | |||||
| Infections in 6 weeks before | |||||||||||||||
| Gastrointestinal infection | 1 (0.4) | 2 (8) | 1 (2) | 4 (22) | 0 | 0 | 0 | 2 (29) | NA | 2 (8) | |||||
| Influenza-like illness | 3 (1) | 8 (32) | 0 | 2 (11) | 1 (0.3) | 0 | 0 | 0 | NA | 4 (17) | |||||
| Upper respiratory tract infection | 10 (4) | 8 (32) | 3 (5) | 4 (22) | 11 (4) | 5 (17) | 0 | 2 (29) | NA | 0 | |||||
| Influenza-like illness or upper respiratory tract infection (%) | 13 (6) | 12 (48) | 3 (5) | 6 (33) | 12 (4) | 5 (17) | 0 | 2 (29) | NA | 4 (17) | |||||
*NA=not available. No information collected on covariates.